ISRCTN86210347 https://doi.org/10.1186/ISRCTN86210347

The effect of electroconvulsive therapy (ECT) following propofol and etomidate anaesthesia: a randomised double blind trial.

Submission date 30/09/2004	**Recruitment status** Stopped	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data [_] Record updated in last year
Registration date 30/09/2004	**Overall study status** Stopped	
Last Edited 13/04/2011	**Condition category** Mental and Behavioural Disorders	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Richard Venn

Contact details
Worthing & Southlands Hospitals NHS Trust
Worthing Hospital
Lyndhurst Road
Worthing
United Kingdom
BN11 2DH
+44 (0)1903 205111 x 5151
richard.venn@wash.nhs.uk

Additional identifiers

Protocol serial number
N0283136357

Study information

Scientific Title

Study objectives
1. To investigate whether an increased stimulus dose is required to produce a tonic/clonic convulsion duration of greater than or equal to 15 s when propofol is used as an alternative to etomidate for anaesthesia during electroconvulsive therapy (ECT).
2. To investigate whether the incidence of cognitive side-effects is influenced independently by the anaesthetic agents propofol and etomidate, or as a consequence of differences in stimulus dose required for ECT. (Cognitive side effects to be measured by Folstein Mini-Mental State Examination [FMM], Paired Associate Learning Test [PALT], and subjective rating of memory).

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised double blind controlled trial

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Mental and Behavioural Disorders: Electroconvulsive therapy (ECT)

Interventions
1. Etomidate (smallest amount of induction agent to achieve loss of consciousness)
2. Propofol (smallest amount of induction agent to achieve loss of consciousness)

Added 21 July 2008: the trial was discontinued in 2006 due to poor recruitment.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
propofol and etomidate

Primary outcome(s)
Evaluation of depression by Beck Depression Inventory and Clinician's Global Impression of Change, number of ECT sessions, duration of motor and EEG seizure, evaluation of cognitive side effects by Folstein Mini-Mental State Examination, Paired Associate Learning Test and subjective rating of memory.

Key secondary outcome(s)

Not provided at time of registration

Completion date
01/01/2006

Reason abandoned (if study stopped)
Lack of staff/facilities/resources

Eligibility

Key inclusion criteria
Patients, over 18 years old, with a major depressive illness who are to receive electroconvulsive therapy (ECT), and who have given written informed consent for the study.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2003

Date of final enrolment
01/01/2006

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Worthing & Southlands Hospitals NHS Trust
Worthing

United Kingdom
BN11 2DH

Sponsor information

Organisation
Department of Health

Funder(s)

Funder type
Government

Funder Name
Sussex NHS Research Consortium (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2006		Yes	No